News Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 10:05:12 06/02/2026 pm IST			5-day change	1st Jan Change
60.50 ^GBX	+0.83%		+17.48%	+4.31%

21/01	Avacta Therapeutics Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug Application for the Second Pre\|Cision® Medicine, Fap-Exatecan	CI
21/01	EARNINGS AND TRADING: Kenmare meets guidance, plans to lower costs	AN

04/02	Avacta Therapeutics Announces Two Key Clinical Updates to its Faridoxorubicin Clinical Program	CI
03/02	Avacta reports progress in faridoxorubicin clinical programme	AN
03/02	Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program	GL
03/02	Avacta reports progress in faridoxorubicin clinical programme	AN
03/02	Avacta Group Updates Trial Protocol in Faridoxorubicin Program	MT
03/02	Avacta Therapeutics says cardiac dosing limit removed in Faridoxorubicin program	RE
21/01	Avacta Therapeutics Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug Application for the Second Pre\|Cision® Medicine, Fap-Exatecan	CI
21/01	EARNINGS AND TRADING: Kenmare meets guidance, plans to lower costs	AN
21/01	Avacta announces US FDA clearance of the investigational new drug application for the second pre\|CISION medicine, FAP-Exatecan	RE
21/01	Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre\|CISION® Medicine, FAP-Exatecan (AVA6103)	GL
21/01	Avacta Therapeutics Wins US FDA Nod to Start Early-stage Trial of Cancer Drug FAP-Exd	MT
20/01	EARNINGS AND TRADING: Treatt cuts dividend after "challenging year"	AN
20/01	Avacta Announces Year-end Trading Update	GL
18/12	Avacta : Research & Development Spotlight Series, Episode 13	PU
18/12	Avacta Reports New Pharmacology Data for Fap-Exd	CI
18/12	Avacta Group Plc - Special Call
18/12	Avacta Therapeutics Announces Faridoxorubicin Phase 1B Cohort Demonstrates Clinically Meaningful Tumor Shailage in Patients with Salivary Metals Cancer	CI
17/12	Avacta says salivary gland cancer drug shrinks tumour	AN
17/12	Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers	GL
17/12	Avacta's Salivary Gland Cancer Therapy Shows Efficacy in Early-stage Study	MT
17/12	Avacta : Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers	PU
08/12	Avacta to announce initial phase 1b data on faridoxorubicin	AN
03/11	Avacta Therapeutics Finalizes Share Placing, Convertible Bond Amendments	MT
27/25/27	Avacta presents first preclinical data from dual payload pre, CISION medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets	AQ
25/25/25	Avacta presents first preclinical data from dual payload pre\|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Filters